Literature DB >> 2291561

The development of hydroxypyridin-4-ones as orally active iron chelators.

R C Hider1, S Singh, J B Porter, E R Huehns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2291561     DOI： 10.1111/j.1749-6632.1990.tb24320.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

Review 1.  Clinical research: a tale of two studies.

Authors:  David G Nathan
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis.

Authors:  R A Yokel
Journal:  Biol Trace Elem Res       Date:  1996       Impact factor: 3.738

3.  Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat.

Authors:  S Singh; R Choudhury; R O Epemolu; R C Hider
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jan-Mar       Impact factor: 2.441

Review 4.  Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

5.  Inhibition of growth of Histoplasma capsulatum yeast cells in human macrophages by the iron chelator VUF 8514 and comparison of VUF 8514 with deferoxamine.

Authors:  S L Newman; L Gootee; V Stroobant; H van der Goot; J R Boelaert
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 6.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.